This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imai, Y. Articles by Sugimoto, Y. Search for Related Content PubMed PubMed Citation Articles by Imai, Y. Articles by Sugimoto, Y.

Estrogen-Mediated Post transcriptional Down-regulation of Breast Cancer Resistance Protein/ABCG2

¹ Division of Molecular Biotherapy, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo, and ² Department of Chemotherapy, Kyoritsu University of Pharmacy, Minato-ku, Tokyo, Japan

Requests for reprints: Yoshikazu Sugimoto, Department of Chemotherapy, Kyoritsu University of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. Fax: 81-35400-2669; E-mail: sugimoto-ys{at}kyoritsu-ph.ac.jp.

Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor (ER)–positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 ß-Estradiol (E₂) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ER-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E₂ potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/BCRP cells. Antiestrogen tamoxifen partially reverses E₂-mediated BCRP down-regulation in MCF-7 and MCF-7/BCRP cells and treatment of MCF-7/BCRP cells with an ER small interfering RNA abolished E₂-mediated BCRP down-regulation, suggesting that interaction of E₂ and ER is necessary for BCRP down-regulation. E₂ does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E₂-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.

Key Words: BCRP • ABCG2 • estrogen • down-regulation • ER

This article has been cited by other articles:

				M. Honorat, A. Mesnier, J. Vendrell, J. Guitton, I. Bieche, R. Lidereau, G. D Kruh, C. Dumontet, P. Cohen, and L. Payen ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor {alpha} expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells Endocr. Relat. Cancer, March 1, 2008; 15(1): 125 - 138. [Abstract] [Full Text] [PDF]

				H. Wang, E.-W. Lee, L. Zhou, P. C. K. Leung, D. D. Ross, J. D. Unadkat, and Q. Mao Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells Mol. Pharmacol., March 1, 2008; 73(3): 845 - 854. [Abstract] [Full Text] [PDF]

				M. Vore and M. Leggas Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression Mol. Pharmacol., March 1, 2008; 73(3): 613 - 615. [Abstract] [Full Text] [PDF]

				K. Katayama, S. Yoshioka, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol. Cancer Ther., July 1, 2007; 6(7): 2092 - 2102. [Abstract] [Full Text] [PDF]

				B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]

				W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006. [Abstract] [Full Text] [PDF]

				H. Wang, L. Zhou, A. Gupta, R. R. Vethanayagam, Y. Zhang, J. D. Unadkat, and Q. Mao Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E798 - E807. [Abstract] [Full Text] [PDF]

				F. R. Simon, M. Iwahashi, L.-J. Hu, I. Qadri, I. M. Arias, D. Ortiz, R. Dahl, and E. Sutherland Hormonal regulation of hepatic multidrug resistance-associated protein 2 (Abcc2) primarily involves the pattern of growth hormone secretion Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G595 - G608. [Abstract] [Full Text] [PDF]

				G. Merino, A. E. van Herwaarden, E. Wagenaar, J. W. Jonker, and A. H. Schinkel Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver Mol. Pharmacol., May 1, 2005; 67(5): 1765 - 1771. [Abstract] [Full Text] [PDF]